MX2009006947A - Derivados de pirimidona 6-heterociclica 2-sustituida. - Google Patents

Derivados de pirimidona 6-heterociclica 2-sustituida.

Info

Publication number
MX2009006947A
MX2009006947A MX2009006947A MX2009006947A MX2009006947A MX 2009006947 A MX2009006947 A MX 2009006947A MX 2009006947 A MX2009006947 A MX 2009006947A MX 2009006947 A MX2009006947 A MX 2009006947A MX 2009006947 A MX2009006947 A MX 2009006947A
Authority
MX
Mexico
Prior art keywords
substituted
protein kinase
tau protein
heterocyclic
inhbitors
Prior art date
Application number
MX2009006947A
Other languages
English (en)
Inventor
Fumiaki Uehara
Toshiyuki Kohara
Kenji Fukunaga
Kazutoshi Watanabe
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MX2009006947A publication Critical patent/MX2009006947A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Un compuesto representado por la fórmula (I), un isómero ópticamente activo de él o una sal farmacéutica aceptable de él (ver fórmula I) en donde cada R1 representa un átomo de hidrógeno o similar; X representa un átomo de oxígeno o similar; A representa un grupo cicloalquilo de C3-C7, un grupo arilo de C6-C10 o un grupo heterocíclico; R6 representa un átomo de halógeno o similar; s representa 0 o un número entero de 1 a 5; Q representa un anillo de piridina que puede ser sustituido o un anillo de pirimidina; y R2 representa un átomo de hidrógeno o similar, que se usa para el tratamiento preventivo y/o terapéutico de una enfermedad provocada por la actividad anormal de la tau proteína cinasa 1 tales como enfermedades neurodegenerativas (por ejemplo, enfermedad de Alzheimer).
MX2009006947A 2006-12-26 2007-12-26 Derivados de pirimidona 6-heterociclica 2-sustituida. MX2009006947A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006357476 2006-12-26
PCT/JP2007/075380 WO2008078837A1 (en) 2006-12-26 2007-12-26 2-substituted-6-heterocyclic pyrimidone derivatives as tau protein kinase 1 inhbitors

Publications (1)

Publication Number Publication Date
MX2009006947A true MX2009006947A (es) 2009-07-10

Family

ID=39144331

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006947A MX2009006947A (es) 2006-12-26 2007-12-26 Derivados de pirimidona 6-heterociclica 2-sustituida.

Country Status (16)

Country Link
US (1) US8592417B2 (es)
EP (1) EP2097409B1 (es)
JP (1) JP5250553B2 (es)
KR (1) KR20090092314A (es)
CN (1) CN101652361A (es)
AR (1) AR064660A1 (es)
AU (1) AU2007339164A1 (es)
CA (1) CA2674557A1 (es)
EA (1) EA200970637A1 (es)
IL (1) IL199378A0 (es)
MX (1) MX2009006947A (es)
NO (1) NO20092759L (es)
NZ (1) NZ577803A (es)
TW (1) TW200845997A (es)
WO (1) WO2008078837A1 (es)
ZA (1) ZA200904236B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200813015A (en) * 2006-03-15 2008-03-16 Mitsubishi Pharma Corp 2-(cyclic amino)-pyrimidone derivatives
AR068439A1 (es) 2007-09-14 2009-11-18 Mitsubishi Tanabe Pharma Corp Derivado de 6-pirimidinil-pirimid-2-ona
TW201043618A (en) 2009-03-10 2010-12-16 Sanofi Aventis Intermediate compound for synthesizing pharmaceutical agent and production method thereof
US8940738B2 (en) * 2009-08-13 2015-01-27 Mitsubishi Tanabe Pharma Corporation Pyrimidone compounds
JP5535310B2 (ja) 2009-08-13 2014-07-02 田辺三菱製薬株式会社 タウプロテインキナーゼ１阻害剤としてのピリミドン誘導体
RU2621050C2 (ru) * 2012-01-12 2017-05-31 Ф. Хоффманн-Ля Рош Аг Гетероциклические производные в качестве рецепторов, ассоциированных со следовыми аминами (taars)
LT3319959T (lt) 2015-07-06 2021-12-27 Alkermes, Inc. Histono deacetilazės hetero-halogeno inhibitoriai
WO2017007755A1 (en) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
TWI770104B (zh) 2017-01-11 2022-07-11 美商羅登醫療公司 組蛋白去乙醯酶雙環抑制劑
MX2020001484A (es) 2017-08-07 2020-08-20 Rodin Therapeutics Inc Inhibidores bicíclicos de la histona desacetilasa.
CN115322197B (zh) * 2022-06-27 2023-09-29 北京师范大学 与Tau蛋白具有亲和力的咪唑并萘啶类化合物及其制备方法与应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI241298B (en) 1998-09-25 2005-10-11 Mitsubishi Chem Corp Pyrimidone derivatives
WO2001070728A1 (en) * 2000-03-23 2001-09-27 Sanofi-Synthelabo 2-[nitrogen-heterocyclic]pyrimidone derivatives
AU2002337499B2 (en) 2001-09-21 2007-08-23 Mitsubishi Pharma Corporation 3-substituted-4-pyrimidone derivatives
MXPA04002661A (es) * 2001-09-21 2004-11-22 Sanofi Aventis Derivados de pirimidona 4, 3-sustituida.
TWI357408B (en) 2003-03-26 2012-02-01 Mitsubishi Tanabe Pharma Corp 3-substituted-4-pyrimidone derivatives
AR050865A1 (es) * 2004-09-09 2006-11-29 Sanofi Aventis Derivados de 2- morfolino-4-pirimidona
PT1805164E (pt) 2004-09-29 2011-04-11 Sanofi Aventis Derivados de 6-(piridinil)-4-pirimidona como inibidores de proteína-cinase tau 1
TW200740779A (en) 2005-07-22 2007-11-01 Mitsubishi Pharma Corp Intermediate compound for synthesizing pharmaceutical agent and production method thereof
TW200813015A (en) 2006-03-15 2008-03-16 Mitsubishi Pharma Corp 2-(cyclic amino)-pyrimidone derivatives
KR20100074183A (ko) 2007-09-14 2010-07-01 사노피-아벤티스 타우 단백질 키나아제 억제제로서 3-메틸-2-((2ｓ)-2-(4-(3-메틸-1,2,4-옥사다이아졸-5-일)페닐)모폴리노)-6-(피리미딘-4-일)피리미딘-4(3ｈ)-온

Also Published As

Publication number Publication date
US8592417B2 (en) 2013-11-26
ZA200904236B (en) 2010-08-25
NZ577803A (en) 2011-11-25
CN101652361A (zh) 2010-02-17
EA200970637A1 (ru) 2009-12-30
TW200845997A (en) 2008-12-01
AU2007339164A1 (en) 2008-07-03
EP2097409B1 (en) 2012-09-12
US20100113775A1 (en) 2010-05-06
JP2010514670A (ja) 2010-05-06
WO2008078837A1 (en) 2008-07-03
CA2674557A1 (en) 2008-07-03
IL199378A0 (en) 2010-03-28
NO20092759L (no) 2009-08-25
AR064660A1 (es) 2009-04-15
KR20090092314A (ko) 2009-08-31
JP5250553B2 (ja) 2013-07-31
EP2097409A1 (en) 2009-09-09

Similar Documents

Publication Publication Date Title
MX2009006947A (es) Derivados de pirimidona 6-heterociclica 2-sustituida.
NO20054331L (no) Substituerte-8-perfluoralkyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on-derivater
NO20054330L (no) 8-substituerte-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on-derivater
TW200626573A (en) Pyrimidone compound
NO20090025L (no) Pyrrolotriazinkinaseinhibitorer
NO20074615L (no) Dihydrotienopyrimidiner for behandling av inflamatoriske sykdommer
NO20071246L (no) Kinazolinonderivater og deres anvendelse som B-RAF-inhibitorer.
TW200635899A (en) Chemical compounds
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
MX2008013836A (es) Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos.
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
MXPA05009574A (es) Derivados de 8'-piridinil- dihidrospiro -[cicloalquil]- pirimido[1, 2a] pirimidin-6- ona y y 8'-pirimidinil- dihidrospiro -[cicloalquil]- pirimido [1, 2a]pirimidin-6 -ona substituidos y su uso contra enfermedades neurodegenerativas.
NO20070199L (no) Substituerte kinazoloner som anti-kreftmidler
NO20091683L (no) Kjemiske forbindelser
WO2007057790A3 (en) Substituted bicyclic pyrimidone derivatives
MX2009004884A (es) Derivados 8-piperidinil-2-piridinil-pirimido [1,2-a] pirimidin-6-ona y 8-piperidinil-2-pirimidinil-pirimido [1,2-a] pirimidin-6-ona sustuidos.
NO20092035L (no) Tiazolylforbindelser anvendbare som kinaseinhibitorer
MX2010002766A (es) 3-metil-2-((2s)-2-(4-(3-metil-l, 2, 4-oxadiazol-5-il-) fenil) morfolino) -6- (pirimidin-4-il) pirimidin-4 (3h) -ona como inhibidor de tau proteina cinasa.
MX2010002765A (es) Derivado de 6-pirimidinil-pirimid-4-ona.
MY153733A (en) Novel quinazoline-2,4-dione derivative, and medical compositions for the prophylaxis and treatment of cranial nerve disease containing the same
EA201270360A1 (ru) Терапевтическое средство от тревожных расстройств
UA88930C2 (en) Amide derivatives
TH106080A (th) อนุพันธ์ของ 2-ที่ถูกแทนที่-6-เฮเทอโรไซคลิค ไพริมิโดน
TH96112A (th) เบนโซออกซาโซลและออกซาโซโลไพริดีนซึ่งมีประโยชน์โดยเป็นสารยับยั้งจานุส (janus) ไคเนส
TH145777A (th) สารอนุพันธ์คาร์บาโมอิลของไบไซคลิกคาร์บอนิลอะมิโน-ไพราโซล ในฐานะโปรดรัก

Legal Events

Date Code Title Description
FA Abandonment or withdrawal